(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología hepatitis virales > DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista >

Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives
Autor(es) : Monge, A. (Antonio)
Alvarez, E. (E)
Sanmartin-Grijalba, C. (Carmen)
Nadal, E. (Ernest)
Ruiz, I. (I)
Font, M. (María)
Martinez-Irujo, J.J. (Juan José)
Santiago, E. (Esteban)
Prieto, I. (Inés)
Lasarte, J.J. (Juan José)
Sarobe, P. (Pablo)
Borras-Cuesta, F. (Francisco)
Palabras clave : Anti-HIV Agents/chemical synthesis
HIV Reverse Transcriptase/antagonists & inhibitors
Pyridines/chemical synthesis
Quinolines/chemical synthesis*
Reverse Transcriptase Inhibitors/chemical synthesis
Fecha incorporación: 1997
Editorial : Informa Healthcare
ISSN: 1029-2322
Cita: Monge A, Alvarez E, San Martin C, Nadal E, Ruiz I, Font M, et al. Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives. Drug Des Discov 1997 Apr;14(4):291-303.
Resumen
The synthesis and preliminary evaluation of new benzo[f]quinoline and pyridine derivatives, obtained by application of the Reissert method and its modifications, as HIV-1 RT inhibitors and anti-infectives are presented. The most active products against HIV-1 RT wild type are the ethyl 2-cyano-1,2-dihydrobenzo[f]quinoline-1-carboxylate 2b, propyl 2-cyano-1,2-dihydrobenzo[f]quinoline-1-carboxylate 2c, and 2-cyano-1-(2'-furoyl)-1,2-dihydrobenzo[f]quinoline 2n, which maintain their activity against the mutant type P236L, resulting inactive against the Y181C type. Using the data previously obtained by our research team for analogous series derived from quinoline as reference, the compounds which have now been obtained present an increase in the cytotoxic character attributable to the introduction of a benzene ring fused with the quinoline base nucleus, as well as a decrease of the activity as HIV-1 RT inhibitors when the quinoline benzenic ring is eliminated.
Enlace permanente: http://hdl.handle.net/10171/21725
Aparece en las colecciones: DA - CIMA - Terapia génica y Hepatología - Inmunología experimental - Artículos de revista
DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista

Ficheros en este registro:

No hay ficheros asociados a este ítem.

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.